SMART MONEY GROUP

[MyzStreet]

Thanks! I hope you grabbed some then. I know you've been on the board a while now. Your board probably got one my first alert on USRM. I guess it can really pay to follow Smart Money board(s)!
With FDA approval this stock is going 3-5 bucks min I bet.
#USRMFTW

Chairman of the Board @ U.S. Stem Cell, Inc. - USRM
Form 4 news ~ was reported late Friday by:
William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by Amazon.com, Inc. in March 2005. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation.
 
Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S. in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents.

He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame.

Dr William P Murphy, Jr discusses Bioheart, Inc on the American Investor
Published on Sep 15, 2014

http://us-stemcell.com/en/about-us/

USRM-U.S. STEM CELL, INC.
3/13/17 CEO Blog Post

http://us-stemcell.com/ceo-blog-u-s-stem-cell-inc-is-off-to-a-great-start-this-year/

Quote:

On regulatory news, following the passing of the 21st Century Cures Act, U.S. Stem Cell, Inc. has applied to the FDA for Regenerative Advanced Therapy or RAT Designation. Thanks to the REGROW component of the Cures Act, The FDA will grant RAT designation for a regenerative medicine therapy that is intended to treat, modify, reverse, or cure a serious or life-threatening disease and demonstrates preliminary clinical evidence that the product has the potential to address unmet medical needs for a disease. We believe that our MyoCell® product meets these requirements as we have demonstrated clinical efficacy in both preclinical and clinical studies including our most recent MARVEL Phase II/III trial. If RAT designation is granted, this could expedite the approval process with the FDA. More information on the FDA’s new RAT Designation can be found here:
https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ucm537670.htm

$$$$$$$$$$$$$$$$$$$$$

U.S. STEM CELL RELEASES POSITIVE 2016 FINANCIAL RESULTS
Posted by U.S. Stem Cell, Inc
 Sunrise, FL – March 15, 2017 – U.S. Stem Cell, Inc., a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies for human and animal patients, is pleased to announce the following results from operations for the year ending December 31, 2016.
“U.S. Stem Cell, Inc. continues to increase revenue, decrease liabilities and decrease operating expenses,” said Mike Tomás, President and CEO of U.S. Stem Cell, Inc. “As a world leader in stem cell research and development for degenerative conditions, we are excited about the industry’s future and dedicated to making a positive impact in our patients’ lives.”
Working with physician partners to offer over 30 protocols to patients, U.S. Stem Cell, Inc. is increasing business opportunities by expanding its services, treatments and therapies both inside and outside the United States.
Financial highlights from 2016 include:
* Revenue up by 38% from $2.2M in 2015 to $3.03M in 2016
* Current liabilities down by $1.9M or 23.8% from $8.0M in 2015 to $6.1M in 2016
* Operating Expenses down 16.5% (or $631,825) from 3.82M in 2015 to $3.19M in 2016
* Net loss improved 136% from $2.6M (gain) in 2015 to $1.15M in 2016
* And for the first time in the company’s history, U.S Stem Cell, Inc. ended the year on a cash positive note: $108,596 cash positive as a result of operations in 2016 compared to $844,690 cash negative from operations in 2015
Operating results for the year ending December 31, 2016 are not necessarily indicative of the results that can be expected for the year ending December 31, 2017.
VIEW PDF HERE

$$$$$$$$$$$$$$$$$$$$$$$$

Video about MYOCELL MUST WATCH

"THE LEADER" IN PHASE III
Stem cell therapy for HF is currently being led by the likes of Bioheart (recently renamed US Stem Cell), which has muscle stem cell therapy candidate Myocell in a phase III trial
http://www.pmlive.com/pharma_intelligence/heart_failure_therapy_embarks_on_a_new_era_933222

https://www.cirm.ca.gov/sites/default/files/files/agenda/Fifteen_Cell_Therapies_PhaseIII_Clinical_Trials.pdf

https://clinicaltrials.gov/ct2/show?term=BIOHEART&rank=3

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668534/?report=classic

Promising Results from Company’s MARVEL Trials on MyoCell
The company recently announced positive clinical results for MyoCell following the first part of its Phase II/III, double-blinded, placebo-controlled clinical trial called MARVEL. Over the 6-month observation period in this trial, the most pronounced changes were seen in the cell-treated groups. The six minute walk distance (6MWD), an established parameter of efficacy utilized in heart failure studies, one of the primary end points in the trial, increased on average by more than 91 meters, or 35%, in cell-treated patients, whereas in the placebo-treated group a decrease of nearly 4 meters was seen. This suggests that patients with heart failure could return to a more active lifestyle after receiving Bioheart’s treatment. No stem cell related safety issues such as arrhythmias, or irregular heartbeat, were observed. An arrhythmia event is disturbing but not serious. In the MARVEL trial pre-treatment with amiodarone enabled patients to avoid arrhythmias.

3 YEAR Clinical TRIAL Approaching Completion Date: estimated March 2017
Official Title:
An Open Label, Non-Randomized, Multi-Center Study To Assess The Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intra-Discally in Patients With Degenerative Disc Disease
https://clinicaltrials.gov/show/NCT02097862

On January 19, 2017, the United States Food and Drug Administration (“FDA”) unveiled a new drug designation process for regenerative advanced therapies, an important first step toward implementation of the regenerative medicine provisions of the 21st Century Cures Act.

Consistent with requests for fast track and breakthrough therapy designations, the FDA only requires that a sponsor describe the preliminary clinical evidence that supports a RAT designation, and does not require the sponsor to submit primary data.
http://www.natlawreview.com/article/fda-adopts-new-designation-process-regenerative-advanced-therapies

MUST READ!! Foot note from a court document regarding USRM.
https://investorshub.advfn.com/uimage/uploads/2017/2/13/dgsooScreen_Shot_2017-02-13_at_1.58.47_PM.png

A world leader in research and development of stem cell and regenerative medicine treatments for patients with degenerative conditions. Pioneered new applications for diseases and developed more than 30 protocols.
http://us-stemcell.com/en/products/

U.S. STEM CELL, INC. provides accredited training programs in regenerative medicine to physicians throughout the world.
https://www.usstemcelltraining.com/

Stem cell peers 1.00 PPS +!
See for yourself -cc'd from HH (thanks HH):
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128248827&txt2find=regenerative

Check out who Is U.S. STEM CELL, INC. CHIEF SCIENCE OFFICER!!
Kristine Comella designations and @ RAAD conference video:
TOP 50 Stem Cell Scientist in the World!!
https://www.cirm.ca.gov/sites/default/files/files/press_release/Top_50_Global_Stem_Cell_Influencers.pdf

and #1 in Bioleaders!!!
http://www.bioleaders-forum.com/speakers/kristin-comella

Comella @ RAAD!! A MUST WATCH!! Lots of info about the Co. along with testimonials:

U.S. STEM CELL, INC. FACEBOOK PAGE
https://www.facebook.com/USStemCell/?fref=nf

LinkedIn: https://www.linkedin.com/m/company/80107

Twitter: https://mobile.twitter.com/USStemCellInc

U.S. STEM CELL, INC YOUTUBE CHANNEL
https://www.youtube.com/user/bioheartinc
Did you know US Stem Cell Clinic can treat ED? Buzz ?! :)

U.S. STEM CELL, INC. personal testimonial:

Additional stem cell info.:
https://singularityhub.com/2017/01/17/stem-cells-are-poised-to-change-health-and-medicine-forever/